Umbilical Cord Mesenchymal Stem Cells and Lung Cancer: We Should Be Hopeful or Hopeless?

Umbilical Cord Mesenchymal Stem Cells and Lung Cancer: We Should Be Hopeful or Hopeless? Publisher Pubmed

Arefnezhad R^{1, 2} ; Helfi M³ ; Okhravijouybari R⁴ ; Goleij P^{5, 6} ; Sargolzaeimoghaddam M⁷ ; Mohammadi H⁸ ; Mahdaviyan N¹ ; Fatemian H⁹ ; Sarg A⁷ ; Jahani S¹⁰ ; Rezaeitazangi F¹¹ ; Nazari A¹²

Show Affiliations

1. Coenzyme R Research Institute, Tehran, Iran
2. Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
3. Department of Medical Physics, School of Medicine, Mashhad University of Medical Science, Mashhad, Iran
4. Onco cardiology department, University of Sorbonne, Paris, France
5. Department of Genetics, Sana Institute of Higher Education, Sari, Iran
6. International Network of Stem Cell (INSC), Universal Scientific Education and Research Network (USERN), Tehran, Iran
7. Istanbul Medipol University, Medical Student, Istanbul, Turkey
8. Student Research Committee, Tehran University of Medical Science, Tehran, Iran
9. School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
10. Department of pathology, University of California, San Diego, United States
11. Department of Anatomy, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran
12. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Tissue and Cell Published:2024

Abstract

Lung cancer (LC) is one of the leading causes of cancer-caused death that possesses a poor prognosis and low survival rate worldwide. In general, LC is classified into small-cell (SCLC) and non-small-cell carcinoma (NSCLC) (involving 80% of patients). Although chemotherapy, radiotherapy, surgery, and molecular-targeted therapy are considered standard approaches for LC treatment, these options have low success with detrimental effects on the life quality of patients. Ergo, recommending treatment with maximum effectiveness and minimum side effects for LC patients has been a substantial challenge for researchers and clinicians in the present era. Recently, mesenchymal stem cells (MSCs)-based strategies have sparked much interest in preventing or treating numerous illnesses. These multipotent stem cells can be isolated from diverse sources, such as umbilical cord, bone marrow, and adipose tissue. Among these sources, umbilical cord mesenchymal stem cells (UC-MSCs) have been in the spotlight of MSCs-based therapies thanks to their considerable advantages, such as high proliferation ability, low immune reactions and tumorigenesis, and easiness in collection and isolation. Some experimental studies have investigated the functionality of intact UC-MSCs and extracellular vesicles, exosomes, and conditioned medium derived from UC-MSCs, as well as genetically engineered UC-MSCs. In this review, we aimed to highlight the influences of these UMSCs-based methods in LC treatment with cellular and molecular insights. © 2024 Elsevier Ltd

Related Docs

View other Related Docs

1. Umbilical Cord Mesenchymal Stem Cells: A Powerful Fighter Against Colon Cancer?, Tissue and Cell (2024)

2. Perspective of Placenta Derived Mesenchymal Stem Cells in Acute Liver Failure, Cell and Bioscience (2020)

3. Stem Cell Therapy Potency in Personalizing Severe Covid-19 Treatment, Stem Cell Reviews and Reports (2021)

4. Human Umbilical Cord Mesenchymal Stem Cells: Heralding an Effective Treatment Against Esophageal Cancer?, Cell Biology International (2023)

5. The Potential Use of Mesenchymal Stem Cells-Derived Exosomes As Micrornas Delivery Systems in Different Diseases, Cell Communication and Signaling (2023)

6. Aging and Cancer Prognosis, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)

7. Mesenchymal Stem Cell Therapies for Covid-19: Current Status and Mechanism of Action, Life Sciences (2020)

8. Cell and Cell-Derivative-Based Therapy for Liver Diseases: Current Approaches and Future Promises, Expert Review of Gastroenterology and Hepatology (2023)

Experts (# of related papers)

View all Related Experts

Reza Malekzadeh (1)

Mohsen Nasiri Toosi (1)

Style	Citing Format
MLA	Arefnezhad R, et al.. "Umbilical Cord Mesenchymal Stem Cells and Lung Cancer: We Should Be Hopeful or Hopeless?." Tissue and Cell, vol. 88, no. , 2024, pp. -.
APA	Arefnezhad R, Helfi M, Okhravijouybari R, Goleij P, Sargolzaeimoghaddam M, Mohammadi H, Mahdaviyan N, Fatemian H, Sarg A, Jahani S, Rezaeitazangi F, Nazari A (2024). Umbilical Cord Mesenchymal Stem Cells and Lung Cancer: We Should Be Hopeful or Hopeless?. Tissue and Cell, 88(), -.
Chicago	Arefnezhad R, Helfi M, Okhravijouybari R, Goleij P, Sargolzaeimoghaddam M, Mohammadi H, Mahdaviyan N, et al.. "Umbilical Cord Mesenchymal Stem Cells and Lung Cancer: We Should Be Hopeful or Hopeless?." Tissue and Cell 88, no. (2024): -.
Harvard	Arefnezhad R et al. (2024) 'Umbilical Cord Mesenchymal Stem Cells and Lung Cancer: We Should Be Hopeful or Hopeless?', Tissue and Cell, 88(), pp. -.
Vancouver	Arefnezhad R, Helfi M, Okhravijouybari R, Goleij P, Sargolzaeimoghaddam M, Mohammadi H, et al.. Umbilical Cord Mesenchymal Stem Cells and Lung Cancer: We Should Be Hopeful or Hopeless?. Tissue and Cell. 2024;88():-.
BibTex	@article{ author = {Arefnezhad R and Helfi M and Okhravijouybari R and Goleij P and Sargolzaeimoghaddam M and Mohammadi H and Mahdaviyan N and Fatemian H and Sarg A and Jahani S and Rezaeitazangi F and Nazari A}, title = {Umbilical Cord Mesenchymal Stem Cells and Lung Cancer: We Should Be Hopeful or Hopeless?}, journal = {Tissue and Cell}, volume = {88}, number = {}, pages = {-}, year = {2024} }
RIS	TY - JOUR AU - Arefnezhad R AU - Helfi M AU - Okhravijouybari R AU - Goleij P AU - Sargolzaeimoghaddam M AU - Mohammadi H AU - Mahdaviyan N AU - Fatemian H AU - Sarg A AU - Jahani S AU - Rezaeitazangi F AU - Nazari A TI - Umbilical Cord Mesenchymal Stem Cells and Lung Cancer: We Should Be Hopeful or Hopeless? JO - Tissue and Cell VL - 88 IS - SP - EP - PY - 2024 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract